Multiple Myeloma

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma [Phase 1]

  Phase 1 study of talquetamab in combination with other anticancer therapies for multiple myeloma; the trial is currently active but not recr…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

  The study on biospecimen collection to identify genetic changes in patients with various cancers undergoing surgery is currently suspended; …

• CLINICAL_TRIALS other · 2026-04-13
  Clinical Trial Update: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

  A Phase 3 study comparing JNJ-79635322 and Teclistamab in relapsed or refractory multiple myeloma is not yet recruiting.

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]

  Phase 1/Phase 2 clinical trial evaluating adaptive dual-target CAR-T cell therapy for relapsed or refractory hematologic malignancies; recru…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

  Clinical trial update assessing the diagnostic performance of a spot urine sample for detecting monoclonal components in patients with multi…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

  This update describes a Phase 2 trial of talquetamab in participants with relapsed or refractory multiple myeloma that is currently recruiti…

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

  Phase 3 study evaluating teclistamab in combination with daratumumab subcutaneously versus DPd or DVd regimens in relapsed or refractory mul…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment [Phase 3]

  This entry describes a Phase 3 trial evaluating talquetamab in combination with daratumumab (or with daratumumab and pomalidomide) versus da…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma [Phase 2]

  A Phase 2 study of JNJ-68284528, a BCMA-targeted CAR-T therapy, in participants with multiple myeloma is currently active but not recruiting…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis [Phase 1]

  This Phase 1 study of JNJ-79635322 in relapsed or refractory multiple myeloma and previously treated AL amyloidosis is currently recruiting.…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma [Phase 1]

  Phase 1 clinical trial update on QXL138AM assessing safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors and mul…

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) [Phase 2]

  Phase 2 clinical trial update evaluating Ulixertinib (BVD-523) in cancers with targeted genetic alterations under MATCH Subprotocol Z1L; the…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse [Phase 2]

  Phase 2 clinical trial assessing the investigational combination of daratumumab and teclistamab versus standard regimens in high-risk relaps…

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

  Phase 1 dose-escalation study evaluating talquetamab in participants with relapsed or refractory multiple myeloma; the trial status is activ…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  This entry reports a clinical trial studying real-world current standards of care for participants with relapsed or refractory multiple myel…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating the safety and anti-tumor activity of REGN7945 in combination with Linvoseltamab in adults with relaps…

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

  This document notes an ongoing Phase 1 clinical trial evaluating JNJ-87562761 in participants with relapsed or refractory multiple myeloma. …

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

  A phase 1 clinical trial investigating pre- and post-change Teclistamab in participants with relapsed or refractory multiple myeloma is curr…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma [Phase 1]

  Phase 1 trial update investigating teclistamab in combination with iberdomide for relapsed or refractory multiple myeloma, currently recruit…

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) [Phase 2]

  This clinical trial update reports a Phase 2 MATCH subprotocol (H) testing trametinib and dabrafenib for cancers with BRAF genetic alteratio…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) [Phase 2]

  This Phase 2 MATCH Screening Trial update describes ongoing evaluation of targeted therapies matched to genetic alterations in patients with…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

  Phase 1 clinical trial evaluating talquetamab and teclistamab, each in combination with a PD-1 inhibitor, for relapsed or refractory multipl…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

  Prospective collection, storage, and reporting of data on patients undergoing hematopoietic stem cell transplantation using a standard prepa…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma [Phase 2]

  A Phase 2 trial evaluating a quadruplet combination of daratumumab, carfilzomib, lenalidomide, and low-dose dexamethasone (DKRd) in newly di…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

  This clinical trial update describes a Phase 1/2 study of Teclistamab in Japanese participants with relapsed or refractory multiple myeloma.…